アクアバウンティ・テクノロジーズ社、2023年第4四半期および通期決算を発表

マサチューセッツ州ハーバード、2024年4月1日--生産性と持続可能性を高める技術を活用した陸上養殖企業であるアクアバウンティ・テクノロジーズ社（NASDAQ: AQB、以下「アクアバウンティ」または「当社」）は本日、2023年12月31日を期末とする第4四半期および通年の業績を発表した。

2023年第4四半期および通年のハイライトと最近の動向

Management Commentary

「アクアバウンティの取締役会長兼最高経営責任者であるシルヴィア・ウルフは、「2023年度の業績は、その年に直面した財務上および経営上の課題を示すものです。「インディアナ州の農場での収穫が制限されたまま年を迎えましたが、これは加工棟の修理が必要だったためです。5月初旬に施設が完全に操業を再開した頃には、アトランティックサーモンの市場価格は下落し始めていました。これは第2四半期、第3四半期と続き、第4四半期のホリデーシーズンに部分的に回復したのみであった。その結果、総生産量は14％増加したにもかかわらず、前年同期比で減収となった。2023年度の純損失は前年度より増加しましたが、これは主に州消費税、弁護士費用、外部コンサルティングの支出が急増したためです。また、オハイオ州の農場建設費の見積もりが大幅に上昇したことも影響し、6月に建設活動と地方債融資の一時停止を余儀なくされました。



「このような課題に直面し、私たちはバランスシートを強化し、キャッシュ・ランウェイを増やすために、さまざまな資金調達手段を検討し始めました。私たちは2024年2月、キャッシュポジションを高め、継続的なキャッシュバーンを減らすため、インディアナ州の農場事業を売却する決断を下したことを発表しました。さらに、ベレンソン・アンド・カンパニーを投資銀行として起用し、当社の抵当権のない資産を担保とする負債性資金調達や、オハイオ農場の建設を再開・完了し、長期的な成長戦略を追求するために必要な追加的な資金調達の選択肢について助言を受けました。



「当社のPEI養殖場は、卵の孵化能力を追加することで操業を拡大し続けており、これにより、サケ養殖業者に販売する非遺伝子組み換えのアトランティックサーモンの卵と稚魚の供給量を増やすことができます。さらに、当社の研究開発チームは、遺伝学、育種、魚の健康、栄養学において進歩を続けている。当社には、当社の課題に対処し、将来の成長を支えるために必要な措置を講じることに専念している、熱心で献身的な経営陣がいます。



「近い将来、株主の皆さんに最新情報をお伝えできることを楽しみにしています」とウルフは締めくくった。

About AquaBounty

アクアバウンティ・テクノロジーズ社（NASDAQ：AQB）は、陸上での持続可能な水産養殖の最初から最後までにおけるリーダーであると確信しています。種苗から育成までの垂直統合型企業として、魚の繁殖、遺伝学、健康と栄養における数十年にわたる専門知識を活用し、食糧不安と気候変動問題に対処する破壊的ソリューションを提供しています。私たちは、効率的、持続可能、かつ収益性の高い方法で世界に食料を供給することを約束します。アクアバウンティ社は、安全・安心で持続可能なプロセスを経て、注意深く監視された陸上養殖場で魚を育てることにより、近隣の市場に新鮮なアトランティックサーモンを提供している。

当社の陸上再循環養殖システム（「RAS」）農場は、米国インディアナ州にある育成農場とカナダ・プリンスエドワード島にある種苗・卵生産農場を含み、主要な消費市場に近く、病気を予防し、野生魚の個体群を保護するために複数のレベルの魚の封じ込めを含むように設計されている。アクアバウンティは、抗生物質や汚染物質を一切使用しない栄養価の高いサーモンを養殖しており、従来の海でのケージ養殖に比べ、二酸化炭素排出量を削減し、海洋生態系を汚染するリスクのないソリューションを提供している。アクアバウンティの詳細については、www.aquabounty.com をご覧いただくか、Facebook、X、LinkedIn、Instagramでフォローしてください。

Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended, including regarding potential financing alternatives for the Company, its operations, and construction of its Ohio farm, as well as a potential sale of the Company’s Indiana farm operation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these statements because they involve significant risks and uncertainties about AquaBounty. AquaBounty may use words such as “continue,” “believe,” “will,” “may,” “expect,” the negative forms of these words and similar expressions to identify such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are, our history of net losses and the likelihood of future net losses; our ability to continue as a going concern; our ability to raise substantial additional capital on acceptable terms, or at all, which is required to implement our business strategy as planned, or at all; our ability to raise additional funds in sufficient amounts on a timely basis, on acceptable terms, or at all; our ability to attract and retain key personnel, including key management personnel; our ability to retain and reengage key vendors and engage additional vendors, as needed; our ability to obtain approvals and permits to construct and operate our farms without delay; increases in interest rates; delays and defects that may prevent the commencement of farm operations; rising inflation rates; our ability to finance our Ohio farm through the placement of municipal bonds, which may require restrictive debt covenants that could limit our control over the farm’s operation and restrict our ability to utilize any cash that the farm generates; our ability to manage our growth, which could adversely affect our business; risks related to potential strategic acquisitions, investments or mergers; high customer concentration, which exposes us to various risks faced by our major customers; ethical, legal, and social concerns about genetically engineered products; our ability to gain consumer acceptance of our genetically engineered Atlantic salmon (“GE Atlantic salmon” or “AquAdvantage salmon”) product; the quality and quantity of the salmon that we harvest; a significant fish mortality event in our broodstock or our production facilities; the loss of our GE Atlantic salmon broodstock; disease outbreaks, which can increase the cost of production and/or reduce production harvests; a shutdown, material damage to any of our farms, or lack of availability of power, fuel, oxygen, eggs, water, or other key components needed for our operations; our ability to efficiently and cost-effectively produce and sell salmon at large commercial scale; any contamination of our products, which could subject us to product liability claims and product recalls; security breaches, cyber-attacks and other disruptions could compromise our information, expose us to fraud or liability, or interrupt our operations; our dependence on third parties for the processing, distribution, and sale of our products; any write-downs of the value of our inventory; business, political, or economic disruptions or global health concerns; adverse developments affecting the financial services industry; industry volatility, including fluctuations in commodity prices of salmon; restrictions on Atlantic salmon farming in certain states; agreements that require us to pay a significant portion of our future revenue to third parties; our ability to receive additional government research grants and loans; international business risks, including exchange rate fluctuations; our ability to use net operating losses and other tax attributes, which may be subject to certain limitations; our ability to maintain regulatory approvals for our GE Atlantic salmon and our farm sites and obtain new approvals for farm sites and the sale of our products in other markets; our ability to continue to comply with U.S. Food and Drug Administration regulations and foreign regulations; significant regulations in the markets in which we intend to sell our products; significant costs complying with environmental, health, and safety laws and regulations, and any failure to comply with these laws and regulations; increasing regulation, changes in existing regulations, and review of existing regulatory decisions; lawsuits by non-governmental organizations and others who are opposed to the development or commercialization of genetically engineered products; risks related to the use of the term “genetically engineered,” which will need to be included as part of the acceptable market name for our GE Atlantic salmon, and bioengineering disclosures provided in accordance with U.S. Department of Agriculture regulations; competitors and potential competitors may develop products and technologies that make ours obsolete or garner greater market share than ours; any theft, misappropriation, or reverse engineering of our products could result in competing technologies or products; our ability to protect our proprietary technologies and intellectual property rights; our ability to enforce our intellectual property rights; volatility in the price of our shares of common stock; our ability to maintain our listing on the Nasdaq Stock Market LLC (“Nasdaq”); our success in growing, or our perceived ability to grow, our GE Atlantic salmon successfully and profitably at commercial scale; an active trading market for our common stock may not be sustained; our status as a “smaller reporting company” and a “non-accelerated filer” may cause our shares of common stock to be less attractive to investors; any issuance of preferred stock with terms that could dilute the voting power or reduce the value of our common stock; provisions in our corporate documents and Delaware law could have the effect of delaying, deferring, or preventing a change in control of us; our expectation of not paying cash dividends in the foreseeable future; and other risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”). Forward-looking statements speak only as of the date hereof, and, except as required by law, AquaBounty undertakes no obligation to update or revise these forward-looking statements. For information regarding the risks faced by us, please refer to our public filings with the SEC, available on the Investors section of our website at www.aquabounty.com and on the SEC’s website at www.sec.gov.

会社・投資家情報：アクアバウンティ・テクノロジーズ

investors@aquabounty.com



メディア連絡先：Vince McMorrowFahlgren Mortine(614) 906-1671vince.mcmorrow@Fahlgren.com